Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review - Scorecard - MDSpire
Advertisement
Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review
Clinical Scorecard: Histological Progression from Lung Adenosquamous Carcinoma to Pulmonary Sarcomatoid Carcinoma Following Radical Resection of EGFR Exon-21 L858R Mutation: A Case Study and Review of Existing Literature
At a Glance
Category
Detail
Condition
Pulmonary Sarcomatoid Carcinoma (PSC)
Key Mechanisms
Epithelial-mesenchymal transition (EMT), poor prognosis, resistance to conventional therapies.
Target Population
Patients with lung cancer, particularly those with EGFR mutations.
Care Setting
Oncology, surgical, and multidisciplinary team settings.
Key Highlights
PSC is a rare and aggressive subtype of non-small cell lung cancer (NSCLC).
Histological transformation from adenosquamous carcinoma to PSC can occur after EGFR-TKI treatment.
High PD-L1 expression in PSC may lead to favorable responses to immune checkpoint inhibitors.
No consensus guidelines exist for the management of PSC.
The case study reports a durable complete response to combined immunochemotherapy.
Guideline-Based Recommendations
Diagnosis
Histopathological examination is essential for accurate diagnosis of PSC.
Management
Management is primarily extrapolated from standard NSCLC protocols.
Monitoring & Follow-up
Regular follow-up and imaging are recommended to monitor for recurrence.
Risks
High recurrence rate after surgical resection and poor response to conventional therapies.
Patient & Prescribing Data
A 68-year-old female with early-stage primary lung cancer and EGFR Exon-21 L858R mutation.
The patient received afatinib followed by combined immunochemotherapy with sintilimab.
Clinical Best Practices
Consider multidisciplinary team discussions for treatment planning.
Monitor for histological transformation in patients with EGFR mutations.
